David Haen

Risk-taking investors flock to biotech for its constant flow of events that can spike or crush the stock prices of the companies developing the latest therapies.

This newly public drug developer tripled its stock price in November following positive FDA news.

These medication movers touch most of the prescriptions in the U.S. Are their stocks a buy?

Few biotech companies ever reach that valuation, and if they do, you should snap them up for your portfolio.

Helping people stricken with illness can be richly rewarding in more ways than one.

Early next year, Karyopharm expects to unveil pivotal clinical trial results that could send shares soaring.

This cash-generating small-business lender has maintained or increased its dividend since going public in 2007.

Many investors aren’t aware of the vital roles contract research organizations fulfill for pharmaceutical and biotech companies -- or of the billions they make each year for their services.

Pfizer announced an expedited FDA review for its drug to treat colorectal cancer, which Exact Sciences’ lead diagnostic test also targets.

This favorite of institutional shareholders remains off the radars of most retail investors.

With FDA approval deadlines approaching in 2020, these four drug developers could see substantial gains if they're successful.

The real question is whether growing product sales can outpace increasing R&D expenses.

This leading diagnostic company's stock has nearly quadrupled in value in just over one year.

This is your last chance to buy these companies' stocks before the Food and Drug Administration weighs in on the fates of their key candidate treatments.

The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.

Promising new results in breast cancer will be presented at next week's San Antonio Breast Cancer Symposium. Here's what to look for.

Late-stage clinical trial results provide a chance for investors to gain significant upside from this developer of drugs combating neurological diseases.

These gene-editing trailblazers continue advancing exciting new approaches to treating inherited diseases.

New drugs from these companies seek to enable more patients to receive cutting-edge cell and gene therapies.

Transformative new therapies are changing the treatment landscape for patients with sickle cell disease, and savvy investors can benefit in this David-versus-Goliath scenario. Which one is the better buy today?